Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 14,454 | 11,834 | 21,793 | 5,334 | 7,757 |
| Cost of Goods | 1,284 | 739 | 654 | 227 | 143 |
| Gross Profit | 13,170 | 11,095 | 21,140 | 5,108 | 7,614 |
| Operating Expenses | 35,575 | 30,329 | 26,200 | 25,364 | 21,805 |
| Operating Income | -22,121 | -18,495 | -4,407 | -20,030 | -14,048 |
| Interest Expense | 849 | 848 | 0 | 0 | 0 |
| Other Income | 58 | 55 | 1 | 24 | 27 |
| Pre-tax Income | -22,912 | -19,288 | -4,406 | -20,006 | -14,021 |
| Net Income Continuous | -22,912 | -19,288 | -4,406 | -20,006 | -14,021 |
| Net Income | $-22,912 | $-19,288 | $-4,406 | $-20,006 | $-14,021 |
| EPS Basic Total Ops | -0.20 | -0.17 | -0.03 | -0.18 | -0.13 |
| EPS Basic Continuous Ops | -0.20 | -0.17 | -0.04 | -0.18 | -0.13 |
| EPS Diluted Total Ops | -0.20 | -0.17 | -0.03 | -0.18 | -0.13 |
| EPS Diluted Continuous Ops | -0.20 | -0.17 | -0.04 | -0.18 | -0.13 |
| EBITDA(a) | $-21,509 | $-18,018 | $-4,124 | $-19,744 | $-13,776 |